Irinotecan and oxaliplatin based regimens of second-line treatment in gastrointestinal neuroendocrine carcinoma (GI-NEC) patients: A retrospective study

#3209

Introduction: Determination of second line treatment in metastatic gastrointestinal neuroendocrine carcinoma (GI-NEC) remains in controversy.

Aim(s): To investigate specific second line treatment in GI-NEC in China.

Materials and methods: This is a retrospective study in which patients immunohistochemically confirmed as metastatic GI-NEC at Peking university cancer hospital from 2010 to 2019 were involved.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhang J, Li J, Lu M, Shen L,

Keywords: gastrointestinal neuroendocrine carcinoma, second-line treatment, survival analysis, overall response rate,